Skip to main content
OpenTrials
Completed

NCT Number: NCT02420015

Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia

This study is designed to evaluate if a treatment the investigators call iCOMMIT is effective at helping smokers with schizophrenia stop smoking. iCOMMIT is a smoking cessation treatment that combines mobile technology with behavioral strategies, counseling, and medications.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Schizophrenia Behavior Cigarette Smoking Mental Disorders Schizophrenia Spectrum and Other Psychotic Disorders Smoking Tobacco Smoking Tobacco Use

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Duke University Medical Center

Durham, North Carolina, 27706, United States

About this study

The purpose of this 2-arm randomized controlled trial (RCT) is to evaluate the efficacy of Multi-Component Mobile-enhanced Treatment for Smoking Cessation (iCOMMIT) in helping individuals with schizophrenia or other psychotic disorders stop smoking. Eligible participants will be randomized to receive iCOMMIT, which includes smoking cessation counseling, pharmacotherapy, and mobile technology components, or a control intervention that includes smoking cessation counseling and pharmacotherapy, but no mobile technology components. The control condition represents an intensive standard of care and helps control for monitoring, counselor, time, and attention effects.

The primary outcome for the study will be self-reported and bio-verified prolonged smoking abstinence at the 6-month follow-up. Self-reported prolonged abstinence will be verified by saliva cotinine assay. Secondary outcomes will include 7- and 30-day point prevalence abstinence at each assessment, where abstinence is defined as no tobacco use in the prior 7 or 30 days.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Currently smoke at least ten cigarettes a day
  • Have been smoking for at least one year
  • Meet criteria for schizophrenia, schizoaffective disorder, or another psychotic disorder based on structured clinical interview
  • Can speak and write fluent conversational English
  • Are between 18 and 70 years of age
  • Are willing to make a smoking cessation attempt
  • Score 26 or higher on the Montreal Cognitive Assessment

Exclusion criteria

  • Have a history of myocardial infarction in the past 6 months
  • Have a contraindication to NRT with no medical clearance from the primary care provider or study physician
  • Use and unwillingness to stop use of other forms of nicotine such as cigars, pipes, or chewing tobacco
  • Are pregnant
  • Meet criteria for a current manic episode based on structured clinical interview
  • Are currently enrolled in another smoking cessation trial
  • Are currently imprisoned or in psychiatric hospitalization

Treatment and study plan

Nicotine Replacement Therapy

Drug

Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings

Other names: nicotine gum, patch, inhaler, and/or lozenge

bupropion

Drug

All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up

Other names: Zyban

cognitive-behavioral smoking cessation counseling

Behavioral

Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.

Mobile Contingency Management

Behavioral

Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence.

Other names: mCM

Stay Quit Coach

Behavioral

Stay Quit Coach is a smart phone application that serves as a source of readily available support and information for adults who are already in treatment to quit smoking and to help them stay quit after treatment. The app guides user in creating tailored plans that include their personal reasons for quitting, interactive tools to help users cope with urges to smoke, motivational messages, support contacts to help users stay smoke free and how to address lapses. Participants assigned to this condition will be asked to use Stay Quit Coach from Session 2 through the 6-month follow-up.

SMS text messaging

Behavioral

Patients assigned to this condition will receive text messages relevant to their current status in their smoking quit attempt, including messages reminding participants to take their smoking cessation medication.

Other names: texting

Primary outcomes

  1. Number of Participants Who Self-report Prolonged Abstinence

    Time frame: 6 month follow-up

    Prolonged abstinence will exclude tobacco use in the first two weeks following the quit date, as is consistent with other smoking cessation trials.

  2. Number of Participants Whose Prolonged Abstinence is Bio-verified

    Time frame: 6 month follow-up

    Self-reported prolonged abstinence (primary outcome) will be verified by cotinine assay. Saliva samples will be collected from participants who self-report prolonged abstinence at each follow-up.

Secondary outcomes

  1. Number of Participants Who Report 7 Day Point Prevalence Abstinence

    Time frame: 3 months post-quit attempt (Session 5)

    Secondary smoking outcomes will include 7-day point prevalence abstinence at each assessment, where abstinence is defined as no tobacco use in the prior 7 days.

  2. Number of Participants Who Report 30 Day Point Prevalence Abstinence

    Time frame: 3 months post-quit attempt (Session 5)

    Secondary smoking outcomes will include 30-day point prevalence abstinence at each assessment, where abstinence is defined as no tobacco use in the prior 30 days.

  3. Number of Participants Who Report 7 Day Point Prevalence Abstinence

    Time frame: 6 months post-quit attempt (Session 6)

    Secondary smoking outcomes will include 7-day point prevalence abstinence at each assessment, where abstinence is defined as no tobacco use in the prior 7 days.

  4. Number of Participants Who Report 30 Day Point Prevalence Abstinence

    Time frame: 6 months post-quit attempt (Session 6)

    Secondary smoking outcomes will include 30-day point prevalence abstinence at each assessment, where abstinence is defined as no tobacco use in the prior 30 days.

Sponsors and collaborators

Lead sponsor

Duke University

Other

Registry information

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Apr 17, 2015
Registry last updated
Jul 10, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.